Acquiring signalling specificity from the cytokine receptor gp130

Trends in Genetics

Volumn 20, Issue 1, 2004, Pages 23-32

  Ernst, Matthias ^a   Jenkins, Brendan J ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT1 PROTEIN; STAT3 PROTEIN;

AMINO ACID SUBSTITUTION; CELL SPECIFICITY; COMPARATIVE STUDY; GENE EXPRESSION; GENE TARGETING; KNOCKOUT MOUSE; NONHUMAN; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 0346157324     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2003.11.003     Document Type: Review

References (79)

1. Marshall C.J. Specificity of receptor cytokine receptor signalling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 80:1995;179-185.
2. Schweitzer R., Shilo B.Z. A thousand and one roles for the Drosophila EGF receptor. Trends Genet. 13:1997;191-196.
3. Mills A.A. Changing colors in mice: an inducible system that delivers. Genes Dev. 15:2001;1461-1467.
4. Boulay J.L., et al. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity. 19:2003;159-163.
5. Heinrich P.C., et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374:2003;1-20.
6. Boulanger M.J., et al. Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex. Science. 300:2003;2101-2104.
7. Jones S.A., Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim. Biophys. Acta. 1592:2002;251-263.
8. Hirano T., et al. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells. 12:1994;262-277.
9. Hirano T., et al. Signalling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 8:1997;241-252.
10. Peters M., et al. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood. 92:1998;3495-3504.
11. Hurst S.M., et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 14:2001;705-714.
12. Atreya R., et al. Blockade of interleukin 6 trans signalling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6:2000;583-588.
13. Starr R., et al. Distinct roles for leukemia inhibitory factor receptor α-chain and gp130 in cell type-specific signal transduction. J. Biol. Chem. 272:1997;2-19986.
14. Stahl N., et al. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science. 267:1995;1349-1353.
15. Li W., et al. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol. Cell. Biol. 14:1994;509-517.
16. Cohen P. The regulation of protein function by multisite phosphorylation - a 25 year update. Trends Biochem. Sci. 25:2000;596-601.
17. Lehmann U., et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signalling through gp130. J. Biol. Chem. 278:2003;661-671.
18. Krebs D.L., Hilton D.J. SOCS proteins: negative regulators of cytokine signalling. Stem Cells. 19:2001;378-387.
19. Nicholson S.E., et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18:1999;375-385.
20. Schmitz J., et al. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275:2000;12848-12856.
21. Chung C.D., et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 278:1997;1803-1805.
22. Liu B., et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc. Natl. Acad. Sci. U. S. A. 95:1998;10626-10631.
23. Jackson P. A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev. 15:2001;3053-3058.
24. Yamanaka Y., et al. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J. 15:1996;1557-1565.
25. Fukada T., et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity. 5:1996;449-460.
26. Maina F., et al. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell. 87:1996;531-542.
27. Maina F., et al. Coupling Met to specific pathways results in distinct developmental outcomes. Mol. Cell. 7:2001;1293-1306.
28. Klinghoffer R.A., et al. An allelic series at the PDGFαR locus indicates unequal contributions of distinct signalling pathways during development. Dev. Cell. 2:2002;103-113.
29. Heuchel R., et al. Platelet-derived growth factor β receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signalling. Proc. Natl. Acad. Sci. U. S. A. 96:1999;11410-11415.
30. Tallquist M.D., et al. Retention of PDGFR-β function in mice in the absence of phosphatidylinositol 3′-kinase and phospholipase Cγ signalling pathways. Genes Dev. 14:2000;3179-3190.
31. Soriano P. The PDGF α receptor is required for neural crest cell development and normal patterning of the somites. Development. 124:1997;2691-2700.
32. Ernst M., et al. Defective gp130-mediated signal transducer and activator of transcription (STAT) signalling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J. Exp. Med. 194:2001;189-203.
33. Ohtani T., et al. Dissection of signalling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity. 12:2000;95-105.
34. Tebbutt N.C., et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 8:2002;1089-1097.
35. Kim H., Baumann H. Dual signalling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol. Cell. Biol. 19:1999;5326-5338.
36. Yasukawa H., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4:2003;551-556.
37. Wang D.Z., et al. Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for Sos1 in EGFR signalling and development. Genes Dev. 11:1997;309-320.
38. Partanen J., et al. Opposite phenotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for Fgfr1 in anteroposterior patterning of mouse embryos. Genes Dev. 12:1998;2332-2344.
39. Ernst M., et al. Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells. EMBO J. 13:1994;1574-1584.
40. Saito M., et al. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J. Immunol. 148:1992;4066-4071.
41. Nakajima K., et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 15:1996;3651-3658.
42. Fukada T., et al. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J. 17:1998;6670-6677.
43. McLemore M.L., et al. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity. 14:2001;193-204.
44. Costa-Pereira A.P., et al. Mutational switch of an IL-6 response to an interferon-γ-like response. Proc. Natl. Acad. Sci. U. S. A. 99:2002;8043-8047.
45. Croker B.A., et al. SOCS3 negatively regulates IL-6 signalling in vivo. Nat. Immunol. 4:2003;540-545.
46. Lang R., et al. SOCS3 regulates the plasticity of gp130 signalling. Nat. Immunol. 4:2003;546-550.
47. Atsumi T., et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. 196:2002;979-990.
48. Chen H.W., et al. Mom identifies a receptor for the Drosophila JAK/STAT signal transduction pathway and encodes a protein distantly related to the mammalian cytokine receptor family. Genes Dev. 16:2002;388-398.
49. Nichols J., et al. Physiological rationale for responsiveness of mouse embryonic stem cells to gp130 cytokines. Development. 128:2001;2333-2339.
50. Kiger A.A., et al. Stem cell self-renewal specified by JAK-STAT activation in response to a support cell cue. Science. 294:2001;2542-2545.
51. Tulina N., Matunis E. Control of stem cell self-renewal in Drosophila spermatogenesis by JAK-STAT signalling. Science. 294:2001;2546-2549.
52. Ehret G.B., et al. DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J. Biol. Chem. 276:2001;6675-6688.
53. Hirota H., et al. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4862-4866.
54. Schirmacher P., et al. Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am. J. Pathol. 153:1998;639-648.
55. Peters M., et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6/sIL-6R double transgenic mice. J. Exp. Med. 185:1997;755-766.
56. Masu Y., et al. Disruption of the CNTF gene results in motor neuron degeneration. Nature. 365:1993;27-32.
57. Linker R.A., et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. 8:2002;620-624.
58. DeChiara T.M., et al. Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth. Cell. 83:1995;313-322.
59. Oppenheim R.W., et al. Cardiotrophin-1, a muscle-derived cytokine, is required for the survival of subpopulations of developing motoneurons. J. Neurosci. 21:2001;1283-1291.
60. Bernad A., et al. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity. 1:1994;725-731.
61. Kopf M., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 368:1994;339-342.
62. Romano M., et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 6:1997;315-325.
63. Ohshima S., et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8222-8226.
64. Wang J., et al. Endogenous and exogenous IL-6 inhibit aeroallergen-induced Th2 inflammation. J. Immunol. 165:2000;4051-4061.
65. Wallenius V., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8:2002;75-79.
66. Robb L., et al. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat. Med. 4:1998;303-308.
67. Bilinski P., et al. Maternal IL-11Rα function is required for normal decidua and fetoplacental development in mice. Genes Dev. 12:1998;2234-2243.
68. Stewart C.L., et al. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature. 359:1992;76-79.
69. Escary J.L., et al. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature. 363:1993;361-364.
70. Chesnokova V., et al. Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology. 139:1998;2209-2216.
71. Zhu M., et al. Studies using leukemia inhibitory factor (LIF) knockout mice and a LIF adenoviral vector demonstrate a key anti-inflammatory role for this cytokine in cutaneous inflammation. J. Immunol. 166:2001;2049-2054.
72. Ware C.B., et al. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development. 121:1995;1283-1299.
73. Alexander W.S., et al. Suckling defect in mice lacking the soluble haemopoietin receptor NR6. Curr. Biol. 9:1999;605-608.
74. Yoshida K., et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. U. S. A. 93:1996;407-411.
75. Kawasaki K., et al. Osteoclasts are present in gp130-deficient mice. Endocrinology. 138:1997;4959-4965.
76. Betz U.A., et al. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J. Exp. Med. 188:1998;1955-1965.
77. Jenkins B.J., et al. Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signalling. Exp. Hematol. 30:2002;1248-1256.
78. Plun-Favreau H., et al. The ciliary neurotrophic factor receptor α component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine. EMBO J. 20:2001;1692-1703.
79. Takahashi-Tezuka M., et al. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol. Cell. Biol. 18:1998;4109-4117.